Comparison of the Efficacy and Safety of Low Molecular Weight Heparins and Unfractionated Heparin in the Initial Treatment of Deep Venous Thrombosis. An Updated Meta-Analysis

Drugs

Volumn 52, Issue SUPPL. 7, 1996, Pages 30-37

  Leizorovicz, A ^a,b  

^a HÔPITAL NEUROLOGIQUE   (France)

^b Service de Pharmacologie Clinique   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CERTOPARIN; CY 222; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PARNAPARIN; TINZAPARIN;

BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DEEP VEIN THROMBOSIS; HUMAN; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; STATISTICAL ANALYSIS; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOEMBOLISM; THROMBUS; TREATMENT OUTCOME;

ANTICOAGULANTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; THROMBOEMBOLISM; THROMBOPHLEBITIS;

THROMBUS;

EID: 0030476889     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199600527-00006     Document Type: Review

References (26)

1. Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet 1960; 1: 1309-12
2. Brandjes DPM, Heijhoer H, Büller HR, et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal vein thrombosis. N Engl J Med 1992; 327: 1485-9
3. Leizorovicz A, Simmoneau G, Decousus H, et al. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis. BMJ 1994; 309: 299-304
4. Cochran WG. Some methods of strengthening the common X2 tests. Biometrics 1954; 10: 417-51
5. Fleiss J. Statistical methods for rates and proportions. New York: Wiley, 1973
6. Bratt G, Tornebohm E, Granqvist S, et al. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis. Thromb Haemost 1985; 54: 813-7
7. Holm HA, Handeland GF, Abildgaard U, et al. Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Haemostasis 1986; 16 Suppl. 2: 30-7
8. Faivre R, Neuhart Y, Kieffer Y, et al. Un nouveau traitement des thromboses veineuses profondes: les fractions d'héparine des bas poids moléculaire. Étude randomisée. Presse Med 1988; 17: 197-200
9. Zanghi M, Morici V, Costanzo M, et al. Deep vein thrombosis of the legs: new therapy by means of low molecular weight heparins. J Int Med Res 1988; 16: 474-84
10. Notarbartolo A, Salanitri G, Davi G. et al. Low molecular weight heparin in the short and long-term treatment of deep vein thrombosis in diabetic subjects. Med Praxis 1988; 9: 1-13
11. Étude Multicentrique Française. Traitement des thromboses veineuses profondes consitituées. Étude comparative d'un fragment d'héparine de bas poids moléculaire (Fragmine®) administrée par voie sous-cutanée et de l'héparine standard administrée par voie intraveineuse continue. Rev Med Interne 1989; 10: 375-81
12. Albada J, Nieuwenhuis HK, Sixma JJ. Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study. Circulation 1989; 80: 935-40
13. Harenberg J, Huck K, Bratsch H, et al. Therapeutic application of subcutaneous low molecular-weight heparin in acute venous thrombosis. Haemostasis 1990; 20 Suppl. 1: 205-19
14. Bratt G, Aberg W, Johansson M, et al. Two daily subcutaneous injections of Fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT). Thromb Haemost 1990; 64: 506-10
15. A Collaborative European Multicentre Study. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1991; 65: 251-6
16. Prandoni P, Lensing AWA, Büller HR, et al. Comparison of subcutaneous low molecular weight heparin with intravenous standard heparin in proximal deep vein thrombosis. Lancet 1992; 339: 441-5
17. Lopaciuk S, Meissner AJ, Filipecki S, et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thromb Haemost 1992; 68: 14-8
18. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis. N Engl J Med 1992; 326: 975-82
19. Simonneau G, Charbonnier B, Decousus H, et al. Subcutaneous low molecular weight heparin compared with continuous intravenous unfractionated heparin in the initial treatment of proximal vein thrombosis. A multicenter randomized trial: DVTENOX Study. Arch Intern Med 1993; 153: 1541-6
20. Tedoldi A, Botticella F, Maloberti MR. Antithrombophilic effect of low molecular weight heparins in patients with deep vein thrombosis. Clin Trials Meta-Anal 1993; 28: 215-25
21. Lindmarker P, Holmström M, Granqvist S, et al. Fragmin once daily subcutaneously in a fixed-dose compared with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis [abstract]. Thromb Haemost 1993; 69: 648
22. Luomanmäki K, Hallert C, Kim H. Low molecular weight heparin (Fragmin®) once daily vs continuous infusion of standard heparin in the treatment of DVT [abstract]. Haemostasis 1994 May; 24 Suppl. 1: 248.
23. Fiessinger JN, Lopez Fernandez M, Gatterer E, et al. Fragmin® once daily versus continuous infusion heparin in the treatment of DVT - an European multicentre trial [abstract]. Haemostasis 1994 May; 24 Suppl. 1: 44
24. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 677-81
25. Koopman MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996; 334: 682-7
26. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-5